1. Home
  2. HRMY vs NNNN Comparison

HRMY vs NNNN Comparison

Compare HRMY & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$29.34

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$28.85

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HRMY
NNNN
Founded
2017
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
HRMY
NNNN
Price
$29.34
$28.85
Analyst Decision
Buy
Analyst Count
10
0
Target Price
$46.70
N/A
AVG Volume (30 Days)
605.9K
17.4K
Earning Date
05-05-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
N/A
EPS
2.71
N/A
Revenue
$868,453,000.00
N/A
Revenue This Year
$19.75
N/A
Revenue Next Year
$12.88
N/A
P/E Ratio
$10.72
$446.57
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$6.05
52 Week High
$40.87
$55.65

Technical Indicators

Market Signals
Indicator
HRMY
NNNN
Relative Strength Index (RSI) 56.76 68.28
Support Level $25.92 $26.48
Resistance Level $30.96 $30.70
Average True Range (ATR) 0.82 2.15
MACD 0.42 0.56
Stochastic Oscillator 91.72 93.89

Price Performance

Historical Comparison
HRMY
NNNN

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: